Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Revenues Tumble 76 Percent in Q4; CMDX CEO Watson Steps Down

NEW YORK (GenomeWeb News) — CombiMatrix today said that fourth-quarter revenue plunged 76 percent as R&D spending jumped 24 percent and net loss widened 150 percent.
 
The company also said it has named Mansoor Mohammed to be CEO of CombiMatrix subsidiary CombiMatrix Molecular Diagnostics, replacing Matt Watson, who stepped down to “pursue other opportunities.” Mohammed had been president and COO of CMDX.
 
CMDX said Watson will remain a consultant to the company for three months.
 
Total receipts for the three months ended Dec. 31, 2006, decreased to $859,000 from $3.5 million during the same period last year.
 
Much of the decline came from the loss of revenue from collaboration agreements, which had no receipts in the fourth quarter of 2006 but generated $2.25 million in the same period last year.
 
Array equipment and services revenue decreased to $228,000 from $467,000; government contracts decreased to $511,000 from $864,000 and service contract revenue increased to $120,000 from $47,000.
 
R&D spending increased 87 percent to $2.8 million.
 
Net loss increased 150 percent to $4.5 million from $1.8 million year over year.
 
CombiMatrix had around $14.3 million in cash, cash equivalents, and short term investments as of Dec. 31.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.